Vycor Medical, Inc. reported a revenue of $1.8 million for the fiscal year ending December 31, 2025, marking an 18% increase from the previous year’s revenue of $1.5 million. The growth was primarily driven by increased international sales, particularly in Europe, which accounted for over half of the revenue increase. The company's gross margin decreased to 83% from 89% in 2024, attributed to higher manufacturing costs and a greater mix of international sales. In contrast, NovaVision, Vycor's subsidiary focused on rehabilitation therapies, experienced a decline in revenue, reporting $67,330, an 8% decrease from 2024.
The company’s operating loss from continuing operations improved to $70,190 in 2025, compared to a loss of $106,951 in 2024. This improvement was supported by a reduction in research and development expenses, which fell to $9,963 from $15,325, reflecting ongoing product development efforts. However, selling, general, and administrative expenses rose to $1.46 million, up from $1.36 million in the prior year, largely due to increased stock-based compensation related to an advisory agreement with Maxim Group LLC.
In terms of operational developments, Vycor Medical continues to focus on expanding its market presence in the U.S. and internationally, particularly in underrepresented territories. The company is also pursuing strategic partnerships and acquisitions to enhance its growth strategy. As of December 31, 2025, Vycor had a total of 7 employees and reported a working capital deficit of $4.2 million, which raises concerns about its ability to continue as a going concern. The company has been reliant on its largest shareholder, Fountainhead, for working capital support, although future funding is uncertain.
Geographically, Vycor Medical generated $1.86 million in revenue from the U.S. market, while European sales contributed $4,906. The company’s total assets decreased to $830,420 from $998,117 in 2024, reflecting a decline in cash and accounts receivable. The company’s management has acknowledged the need for additional financing to meet its operational needs and has indicated that it may seek further equity or debt funding, although there are no guarantees regarding the availability of such funding.
Looking ahead, Vycor Medical aims to reduce cash operating losses and improve its financial position. The company is actively exploring strategic acquisitions and partnerships to bolster its growth and market presence. However, the ongoing working capital deficiency and reliance on shareholder support present significant challenges that could impact its operational capabilities and future growth prospects.
About VYCOR MEDICAL INC
Vycor Medical, Inc. develops and markets medical devices for neurosurgery, including the ViewSite Brain Access System, and provides non-invasive vision rehabilitation therapies through NovaVision. Serving hospitals and patients worldwide, it offers minimally invasive surgical tools and digital health therapies. The company leverages regulatory approvals, innovative product development, and strategic partnerships to address neurological and vision impairment markets. Its business model focuses on device sales and therapy services in healthcare.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.